20,819 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 20,819 shares of the biopharmaceutical company’s stock, valued at approximately $108,000.

Other institutional investors also recently bought and sold shares of the company. Certuity LLC purchased a new position in shares of Revance Therapeutics in the second quarter valued at $26,000. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics during the 2nd quarter valued at about $33,000. Hsbc Holdings PLC acquired a new position in Revance Therapeutics during the second quarter worth about $38,000. Nisa Investment Advisors LLC lifted its holdings in shares of Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 18,077 shares in the last quarter. Finally, Creative Planning acquired a new stake in shares of Revance Therapeutics in the third quarter valued at approximately $56,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RVNC. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. HC Wainwright reissued a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th. Barclays reaffirmed an “equal weight” rating and set a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Piper Sandler cut shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.66.

Revance Therapeutics Trading Up 1.9 %

Shares of NASDAQ:RVNC opened at $3.80 on Tuesday. The firm has a market cap of $398.62 million, a price-to-earnings ratio of -1.97 and a beta of 0.95. The stock’s 50-day moving average price is $5.09 and its two-hundred day moving average price is $4.43. Revance Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. As a group, research analysts forecast that Revance Therapeutics, Inc. will post -1.54 earnings per share for the current fiscal year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.